Bausch Health Cos Inc.

BHC-N

NYSE:BHC

31.46
2.13 (7.26%)

Analysis and Opinions about BHC-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
April 5, 2019
The former Valient Pharmaceuticals. It looks like it could rally $10 on a new breakout. Hold off until for a while as he does not see a real trend forming yet. Trade with a $28 stop-loss. (Analysts’ price target is $40.00)
The former Valient Pharmaceuticals. It looks like it could rally $10 on a new breakout. Hold off until for a while as he does not see a real trend forming yet. Trade with a $28 stop-loss. (Analysts’ price target is $40.00)
Jeff Parent B. Eng. FCSI CIM
VP & Portfolio Manager, Chief Investment Officer, Castlemoore Inc.
Price
$25.120
Owned
No
HOLD
HOLD
December 28, 2018
There is no yield, so it falls outside his ranking system. Overall growth in earnings is basically flat. The PE ratio is only 5 times so he feels the market is somewhat skeptical.
There is no yield, so it falls outside his ranking system. Overall growth in earnings is basically flat. The PE ratio is only 5 times so he feels the market is somewhat skeptical.
Robert McWhirter
President, Selective Asset Management
Price
$18.790
Owned
No
COMMENT
COMMENT
December 3, 2018
R&D-to-sales metric steered him away from Valeant (what Bausch used to be named). The current CEO is doing a great job transitioning and paying debt and de-risking the company. They appear to be doing well during this restructuring.
R&D-to-sales metric steered him away from Valeant (what Bausch used to be named). The current CEO is doing a great job transitioning and paying debt and de-risking the company. They appear to be doing well during this restructuring.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$25.280
Owned
No
DON'T BUY
DON'T BUY
September 17, 2018

You have been through ups and down with this one including a name change from Valiant. It has decent price momentum. They are trying to reconcile their balance sheet. Forward numbers look a lot better than backward looking numbers. They are not cheap enough and it is still a volatile stock. They have too much debt so avoid it.

You have been through ups and down with this one including a name change from Valiant. It has decent price momentum. They are trying to reconcile their balance sheet. Forward numbers look a lot better than backward looking numbers. They are not cheap enough and it is still a volatile stock. They have too much debt so avoid it.

Jason Mann
CIO & Co-Founder, Edgehill Patners
Price
$22.550
Owned
Unknown
DON'T BUY
DON'T BUY
August 9, 2018

Formally Valiant. It had a rise and fall from grace. It bottomed over the last year. There is a lot of volatility. They addressed some of the concerns. Investors worry about R&D; and about drugs coming off patent. He does not know about their pipelines. If you can handle the risk, there are few companies where you can play the sector. There are more names in the US in this space that are attractive.

Formally Valiant. It had a rise and fall from grace. It bottomed over the last year. There is a lot of volatility. They addressed some of the concerns. Investors worry about R&D; and about drugs coming off patent. He does not know about their pipelines. If you can handle the risk, there are few companies where you can play the sector. There are more names in the US in this space that are attractive.

Cole Kachur
Senior Wealth Advisor, ScotiaWealth Management
Price
$23.170
Owned
Unknown
Showing 1 to 5 of 5 entries
  • «
  • 1
  • »